More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.

Frias, Juan; Puig Domingo, Manuel; Meneghini, Luigi; Napoli, Raffaele; Liu, Minzhi; Soltes Rak, Erika; Aroda, Vanita R

Frias, Juan; Puig Domingo, Manuel; Meneghini, Luigi; Napoli, Raffaele; Liu, Minzhi; Soltes Rak, Erika; Aroda, Vanita R.

Affiliation

Frias J; National Research Institute, Los Angeles, California.
Puig Domingo M; Germans Trias i Pujol Research Institute, UAB, Badalona, Spain.
Meneghini L; CIBERDEM and CIBERER, Madrid, Spain.
Napoli R; Department of Internal Medicine, University of Texas Southwestern Medical Center and Parkland Health & Hospital System, Dallas, Texas.
Liu M; Department of Translational Medicine, Federico II University School of Medicine, Naples, Italy.
Soltes Rak E; BDM Consulting, Inc., Somerset, New Jersey.
Aroda VR; PRO Unlimited, Inc., Boca Raton, Florida.

Diabetes Obes Metab ; 20(9): 2314-2318, 2018 09.

Article in En | MEDLINE | ID: mdl-29785837

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Hypoglycemic Agents/administration & dosage; Insulin Glargine/administration & dosage; Peptides/administration & dosage; Adult; Blood Glucose/drug effects; Diabetes Mellitus, Type 2/blood; Drug Combinations; Fasting/blood; Female; Glycated Hemoglobin/drug effects; Humans; Hypoglycemia/chemically induced; Kaplan-Meier Estimate; Male; Middle Aged; Time Factors; Treatment Outcome

Key words

GLP-1; glycaemic control; insulin therapy; type 2 diabetes

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Peptides / Diabetes Mellitus, Type 2 / Insulin Glargine / Hypoglycemic Agents Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google